S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

Akero Therapeutics (AKRO) Stock Price, News & Analysis

$25.34
+1.13 (+4.67%)
(As of 02/23/2024 ET)
Today's Range
$24.36
$27.66
50-Day Range
$17.76
$25.34
52-Week Range
$11.25
$58.38
Volume
1.49 million shs
Average Volume
1.09 million shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.86

Akero Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
61.2% Upside
$40.86 Price Target
Short Interest
Bearish
13.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
1.64mentions of Akero Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$2.83 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.82) to ($3.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.92 out of 5 stars

Medical Sector

207th out of 943 stocks

Pharmaceutical Preparations Industry

88th out of 429 stocks


AKRO stock logo

About Akero Therapeutics Stock (NASDAQ:AKRO)

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

AKRO Stock Price History

AKRO Stock News Headlines

Unlicensed crypto exchanges face shutdown in Hong Kong
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Akero Therapeutics Inc.
Biotech Stock Rally Could Soon Take a Breather
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
AMKR, ALKS and CLFD are among after hour movers
Akero Therapeutics Inc AKRO
Akero Therapeutics: Deceptively Promising
11 Analysts Have This to Say About Akero Therapeutics
Akero Therapeutics: Q3 Earnings Insights
Akero Therapeutics (NASDAQ: AKRO)
See More Headlines
Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
2/24/2024
Next Earnings (Estimated)
3/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKRO
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.86
High Stock Price Target
$58.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+61.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-112,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.98 per share

Miscellaneous

Free Float
50,303,000
Market Cap
$1.41 billion
Optionable
Optionable
Beta
-0.43
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Andrew Cheng M.D. (Age 57)
    Ph.D., President, CEO & Director
    Comp: $1.22M
  • Dr. Jonathan M. Young J.D. (Age 54)
    Ph.D., Co-Founder, Executive VP, COO & Secretary
    Comp: $763.3k
  • Dr. Timothy Rolph (Age 70)
    Co-Founder & Chief Scientific Officer
    Comp: $819.4k
  • Mr. William R. White J.D. (Age 51)
    Executive VP, CFO, Treasurer & Head of Corporate Development
    Comp: $768.4k
  • Ms. Catriona YaleMs. Catriona Yale (Age 52)
    Executive VP & Chief Development Officer
    Comp: $754.8k
  • Mr. Patrick Lamy (Age 51)
    Senior Vice President of Commercial Strategy
  • Mr. John J. Schembri (Age 62)
    VP of Finance & Controller














AKRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings
or view top-rated stocks.

What is Akero Therapeutics' stock price target for 2024?

8 brokerages have issued 1 year price objectives for Akero Therapeutics' stock. Their AKRO share price targets range from $33.00 to $58.00. On average, they expect the company's share price to reach $40.86 in the next twelve months. This suggests a possible upside of 61.2% from the stock's current price.
View analysts price targets for AKRO
or view top-rated stocks among Wall Street analysts.

How have AKRO shares performed in 2024?

Akero Therapeutics' stock was trading at $23.35 at the start of the year. Since then, AKRO stock has increased by 8.5% and is now trading at $25.34.
View the best growth stocks for 2024 here
.

When is Akero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 15th 2024.
View our AKRO earnings forecast
.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) posted its earnings results on Monday, November, 13th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.70) by $0.01.

What ETFs hold Akero Therapeutics' stock?
What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.60%), Price T Rowe Associates Inc. MD (6.60%), RTW Investments LP (6.45%), Vanguard Group Inc. (5.54%), Point72 Asset Management L.P. (1.16%) and Goldman Sachs Group Inc. (1.10%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White.
View institutional ownership trends
.

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKRO) was last updated on 2/24/2024 by MarketBeat.com Staff